Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a phase2, randomized, single-blind, placebo controlled and multi-center study in adults with chronic hepatitis B virus. The study is aimed at evaluating efficacy and safety of ASC42 in combination with entecavir and pegylated interferon α-2a in subjects with chronic hepatitis B virus.
Epistemonikos ID: 768a3d321325f63ba1dd796e74d7bbc6679a24b4
First added on: May 09, 2024